CETAsTislelizumabdurvalumabatezolizumab
…hanisms and consistent placebo outcomes, they may be considered CETAs for ES-SCLC first-line treatment, despite potential OS bias fro…
1articles mentioning treatments
1treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: CETAs ×
CETAs
This treatment is selected. Its supporting articles are shown below.